PRESENTATION TITLE
Myeloma from Phase 3 to Phase 0

PRESENTER(S)
Dr. A. Keith Stewart, MBChB, MRCP, FRCPC, MBA
Vice President, Cancer and Director of the Princess Margaret Cancer Program, University Health Network, and regional Vice President, Toronto Central South Regional Cancer Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

PRESENTER BIO

Dr. A. Keith Stewart is the Vice President, Cancer and Director of the Princess Margaret Cancer Program, University Health Network, and Regional Vice-President, Toronto Central South Regional Cancer Program, Ontario Health. 

Dr. Stewart served as the Carlson and Nelson Endowed Director of the Mayo Clinic Center for Individualized Medicine and was recognized as the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s responsibilities at the Mayo Clinic included the application of genomics to human health across the spectrum of discovery, translation, and application to clinical practice.

Dr. Stewart received his medical degree at Aberdeen University Medical School and trained in internal medicine and hematology in Glasgow, Kingston, Toronto, and Boston.  He was Active Staff at the Toronto General and Princess Margaret hospitals from 1992 to 2005 and held the J. Gerald Scott/David G. Whitmore Chair in Hematology and Gene Therapy at the University of Toronto.  In 2002, Dr. Stewart completed a Master’s in Business Administration at the Ivey Business School, University of Western Ontario.

Dr. Stewart has served in several leadership roles across both research and clinical practice in Toronto and at the Mayo Clinic, including as Director of Research at Toronto General Hospital and as Founding Director of the McLaughlin Centre for Molecular Medicine at the University of Toronto. At the Mayo Clinic, he was the Dean for Research in Arizona, and a member of the Arizona Executive Operations Team and Clinical Practice Committees. He has served on multiple boards for both non-profit and commercial organizations, including as a Non-Executive Board member with Genomics England and a member of the Advisory Boards of Helix Inc., Veritas Genetics, Inc., Tempus Inc., and the Multiple Myeloma Research Foundation Investment Committee.

Dr. Stewart has more than 25 years of sustained national funding for a laboratory research program in genomics and biology of multiple myeloma and has led numerous clinical trials of new drugs for this blood cancer. He has held editorial responsibilities for several prominent publications and has authored more than 350 peer reviewed research papers.

VIEWING LOCATIONS
Zoom Registration Link

LEARNING OBJECTIVES

• Develop a familiarity with recent advances in myeloma therapy.
• Review how phase 0 testing can advance novel therapeutics.
• Demonstrate how scientists are exploring drug sensitivity and resistance with multi-omics.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.